Carl Zeiss Meditec AG Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Daniel Wendorff - ODDO BHF Corporate & Markets, Research Division - Analyst : Three, if I may. So one follow-up on the order book questions. Over what period of time is your order book normally transferring into sales? And that would be my first question. Second question would be, how big is your SMILE business suit overall meanwhile in the U.S.? And how is that growing? Or has this been growing over the last few quarters? Any more color you can provide here I would appreciate. And last question, a follow-up on the QUATERA question for the U.S. How does your launch plan overall look like overall for the cataract suit in the U.S.? Also thinking about the Iontech phaco sling technology here. So any more color here would be appreciated.

Question: Sezgi Bice Oezener - HSBC, Research Division - Analyst : My question is, first, I would have 2, please. First about operational cash flows in the first quarter, you shortly commented that it's due to ramp-up of inventories and payables. But can you comment a little bit about the project outlook, to what extent do you expect the correction? And my second question is SG&A expense increased because of trade fairs, but we also know that we weren't quite out of the COVID restrictions yet. So do you think that the rise in SG&A expense came to -- has already happened to its full extent? Or do you expect further rise?